Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z, Dai Z, Zhang X, Zhang L, Peng Y, et al. Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer. 2022;21(1):39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li T, Li J, Chen Z, Zhang S, Li S, Wageh S, Al-Hartomy OA, Al-Sehemi AG, Xie Z, Kankala RK, et al. Glioma diagnosis and therapy: current challenges and nanomaterial-based solutions. J Control Release. 2022;352:338–70.

Article  CAS  PubMed  Google Scholar 

Schaff LR, Mellinghoff IK. Glioblastoma and other primary brain malignancies in adults: a review. JAMA. 2023;329(7):574–87.

Article  PubMed  Google Scholar 

Verdugo E, Puerto I, Medina MA. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment. Cancer Commun. 2022;42(11):1083–111.

Article  Google Scholar 

de Krijger I, Boersma V, Jacobs JJL. REV7: jack of many trades. Trends Cell Biol. 2021;31(8):686–701.

Article  PubMed  PubMed Central  Google Scholar 

Paniagua I, Tayeh Z, Falcone M, Hernandez Perez S, Cerutti A, Jacobs JJL. MAD2L2 promotes replication fork protection and recovery in a shieldin-independent and REV3L-dependent manner. Nat Commun. 2022;13(1):5167.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Krijger I, Fohr B, Perez SH, Vincendeau E, Serrat J, Thouin AM, Susvirkar V, Lescale C, Paniagua I, Hoekman L, et al. MAD2L2 dimerization and TRIP13 control shieldin activity in DNA repair. Nat Commun. 2021;12(1):5421.

Article  PubMed  PubMed Central  Google Scholar 

Kim JH, Kim HR, Patel R. Inactivation of Mad2B enhances apoptosis in human cervical cancer cell line upon cisplatin-induced DNA damage. Biomol Ther. 2023;31(3):340–9.

Article  CAS  Google Scholar 

Vassel FM, Bian K, Walker GC, Hemann MT. Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer. Proc Natl Acad Sci U S A. 2020;117(46):28922–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoshino A, Nakayama C, Jiang SX, Sakurai Y, Kato T, Numata Y, Umezawa A, Ichinoe M, Murakumo Y. Upregulation of REV7 correlates with progression of malignant melanoma. Pathol Int. 2022;72(1):14–24.

Article  CAS  PubMed  Google Scholar 

Ma L, Li X, Zhao X, Sun H, Kong F, Li Y, Sui Y, Xu F. Oxaliplatin promotes siMAD2L2-induced apoptosis in colon cancer cells. Mol Med Rep. 2021;24(3):1–9.

Article  CAS  Google Scholar 

Niimi K, Murakumo Y, Watanabe N, Kato T, Mii S, Enomoto A, Asai M, Asai N, Yamamoto E, Kajiyama H, et al. Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells. Cancer Sci. 2014;105(5):545–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hernando E, Nahle Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature. 2004;430(7001):797–802.

Article  CAS  PubMed  Google Scholar 

Alonso MM, Alemany R, Fueyo J, Gomez-Manzano C. E2F1 in gliomas: a paradigm of oncogene addiction. Cancer Lett. 2008;263(2):157–63.

Article  CAS  PubMed  Google Scholar 

Engelmann D, Putzer BM. The dark side of E2F1: in transit beyond apoptosis. Cancer Res. 2012;72(3):571–5.

Article  CAS  PubMed  Google Scholar 

Zhou J, Tong F, Zhao J, Cui X, Wang Y, Wang G, Kang C, Liu X, Wang Q. Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance. Cancer Biol Med. 2023;20(5):385–400.

Article  PubMed  PubMed Central  Google Scholar 

Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, Hansen AS, Gouw AM, Felsher DW. The MYC oncogene—the grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol. 2022;19(1):23–36.

Article  CAS  PubMed  Google Scholar 

Das SK, Lewis BA, Levens D. MYC: a complex problem. Trends Cell Biol. 2023;33(3):235–46.

Article  CAS  PubMed  Google Scholar 

Duffy MJ, O’Grady S, Tang M, Crown J. MYC as a target for cancer treatment. Cancer Treat Rev. 2021;94:102154.

Article  CAS  PubMed  Google Scholar 

Edwards-Hicks J, Su H, Mangolini M, Yoneten KK, Wills J, Rodriguez-Blanco G, Young C, Cho K, Barker H, Muir M, et al. MYC sensitises cells to apoptosis by driving energetic demand. Nat Commun. 2022;13(1):4674.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther. 2018;3:5.

Article  PubMed  PubMed Central  Google Scholar 

Cencioni C, Scagnoli F, Spallotta F, Nasi S, Illi B. The “superoncogene” myc at the crossroad between metabolism and gene expression in glioblastoma multiforme. Int J Mol Sci. 2023;24(4):4217.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li J, Liao T, Liu H, Yuan H, Ouyang T, Wang J, Chai S, Li J, Chen J, Li X, et al. Hypoxic glioma stem cell-derived exosomes containing Linc01060 promote progression of glioma by regulating the MZF1/c-Myc/HIF1alpha axis. Cancer Res. 2021;81(1):114–28.

Article  CAS  PubMed  Google Scholar 

Llombart V, Mansour MR. Therapeutic targeting of “undruggable” MYC. EBioMedicine. 2022;75:103756.

Article  CAS  PubMed  Google Scholar 

Chen Z, Wang HW, Wang S, Fan L, Feng S, Cai X, Peng C, Wu X, Lu J, Chen D, et al. USP9X deubiquitinates ALDH1A3 and maintains mesenchymal identity in glioblastoma stem cells. J Clin Invest. 2019;129(5):2043–55.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Q, Chen Z, Tang Q, Wang Z, Lu J, You Y, Wang H. USP21 promotes self-renewal and tumorigenicity of mesenchymal glioblastoma stem cells by deubiquitinating and stabilizing FOXD1. Cell Death Dis. 2022;13(8):712.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hersh AM, Gaitsch H, Alomari S, Lubelski D, Tyler BM. Molecular pathways and genomic landscape of glioblastoma stem cells: opportunities for targeted therapy. Cancers. 2022;14(15):3743.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Z, Zhang H, Xu S, Liu Z, Cheng Q. The adaptive transition of glioblastoma stem cells and its implications on treatments. Signal Transduct Target Ther. 2021;6(1):124.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peng L, Fu J, Chen Y, Ming Y, He H, Zeng S, Zhong C, Chen L. Transcription factor SNAI2 exerts pro-tumorigenic effects on glioma stem cells via PHLPP2-mediated Akt pathway. Cell Death Dis. 2022;13(6):516.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marcotte R, Sayad A, Brown KR, Sanchez-Garcia F, Reimand J, Haider M, Virtanen C, Bradner JE, Bader GD, Mills GB, et al. Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance. Cell. 2016;164(1–2):293–309.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, Gill S, Harrington WF, Pantel S, Krill-Burger JM, et al. Defining a cancer dependency map. Cell. 2017;170(3):564–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang LB, Karpova A, Gritsenko MA, Kyle JE, Cao S, Li Y, Rykunov D, Colaprico A, Rothstein JH, Hong R, et al. Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell. 2021;39(4):509–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C, Sjostedt E, Asplund A, et al. Proteomics tissue-based map of the human proteome. Science. 2015;347(6220):1260419.

Article  PubMed  Google Scholar 

Sun D, Wang J, Han Y, Dong X, Ge J, Zheng R, Shi X, Wang B, Li Z, Ren P, et al. TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. Nucleic Acids Res. 2021;49(D1):D1420–30.

Article  CAS  PubMed  Google Scholar 

Yuan H, Yan M, Zhang G, Liu W, Deng C, Liao G, Xu L, Luo T, Yan H, Long Z, et al. CancerSEA: a cancer single-cell state atlas. Nucleic Acids Res. 201